Component

Burosumab anti-FGF23 antibody

Burosumab anti-FGF23 antibody. Species, exposure and limitations are retained in each linked claim.

5 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. At week 24, 43.1% of baseline active fractures were fully healed with burosumab versus 7.7% with placebo.

    Burosumab anti-FGF23 antibody → Active fracture/pseudofracture healing in adults with XLH source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"}
    experimental_model
    Randomized double-blind placebo-controlled phase 3 trial
    exposure
    Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis
    limitations
    FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.
    nutrient_topic
    Phosphorus research collection; topical membership is not evidence of a direct dietary effect. · Phosphorus
    organism
    Human
    plain_language
    The trial also showed a tissue-level healing benefit.
    primary_references
    [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    tissue_or_cell_type
    134 symptomatic adults with X-linked hypophosphatemia
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Phosphorus: metabolism, signaling and nutrient connections (2026-09-17) · lines 1206–1217

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled phase 3 trial · source_derived_draft · unverified_draft

    ### phosphorus-burosumab-fractures At week 24, 43.1% of baseline active fractures were fully healed with burosumab versus 7.7% with placebo. Condition category: machinery_impairment nutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial also showed a tissue-level healing benefit. organism: Human tissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia experimental_model: Randomized double-blind placebo-controlled phase 3 trial limitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation. exposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis evidence_span: {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"} [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    Complete structured claim and evidence

  2. Worst pain and physical function did not achieve significance after the trial’s multiplicity adjustment.

    Burosumab anti-FGF23 antibody → Brief Pain Inventory worst-pain score in adults with XLH source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"}
    experimental_model
    Randomized double-blind placebo-controlled phase 3 trial
    exposure
    Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis
    limitations
    FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.
    nutrient_topic
    Phosphorus research collection; topical membership is not evidence of a direct dietary effect. · Phosphorus
    organism
    Human
    plain_language
    Not every symptom endpoint showed a reliable benefit.
    primary_references
    [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    tissue_or_cell_type
    134 symptomatic adults with X-linked hypophosphatemia

    Phosphorus: metabolism, signaling and nutrient connections (2026-09-17) · lines 1232–1243

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled phase 3 trial · source_derived_draft · unverified_draft

    ### phosphorus-burosumab-pain-null Worst pain and physical function did not achieve significance after the trial’s multiplicity adjustment. Condition category: normal nutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect. plain_language: Not every symptom endpoint showed a reliable benefit. organism: Human tissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia experimental_model: Randomized double-blind placebo-controlled phase 3 trial limitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation. exposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis evidence_span: {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"} [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    Complete structured claim and evidence

  3. Across dosing-interval midpoints, 94.1% on burosumab versus 7.6% on placebo attained mean serum phosphate above the lower limit of normal.

    Burosumab anti-FGF23 antibody → Serum inorganic phosphate concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"}
    experimental_model
    Randomized double-blind placebo-controlled phase 3 trial
    exposure
    Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis
    limitations
    FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.
    nutrient_topic
    Phosphorus research collection; topical membership is not evidence of a direct dietary effect. · Phosphorus
    organism
    Human
    plain_language
    Blocking the wasting signal substantially improved the phosphate measurement.
    primary_references
    [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    tissue_or_cell_type
    134 symptomatic adults with X-linked hypophosphatemia
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Phosphorus: metabolism, signaling and nutrient connections (2026-09-17) · lines 1193–1204

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled phase 3 trial · source_derived_draft · unverified_draft

    ### phosphorus-burosumab-phosphate Across dosing-interval midpoints, 94.1% on burosumab versus 7.6% on placebo attained mean serum phosphate above the lower limit of normal. Condition category: machinery_impairment nutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect. plain_language: Blocking the wasting signal substantially improved the phosphate measurement. organism: Human tissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia experimental_model: Randomized double-blind placebo-controlled phase 3 trial limitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation. exposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis evidence_span: {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"} [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    Complete structured claim and evidence

  4. The WOMAC stiffness endpoint significantly improved versus placebo in the week-24 analysis.

    Burosumab anti-FGF23 antibody → WOMAC stiffness score in adults with XLH source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"}
    experimental_model
    Randomized double-blind placebo-controlled phase 3 trial
    exposure
    Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis
    limitations
    FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.
    nutrient_topic
    Phosphorus research collection; topical membership is not evidence of a direct dietary effect. · Phosphorus
    organism
    Human
    plain_language
    Stiffness improved in the treated XLH group.
    primary_references
    [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    tissue_or_cell_type
    134 symptomatic adults with X-linked hypophosphatemia

    Phosphorus: metabolism, signaling and nutrient connections (2026-09-17) · lines 1219–1230

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled phase 3 trial · source_derived_draft · unverified_draft

    ### phosphorus-burosumab-stiffness The WOMAC stiffness endpoint significantly improved versus placebo in the week-24 analysis. Condition category: normal nutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect. plain_language: Stiffness improved in the treated XLH group. organism: Human tissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia experimental_model: Randomized double-blind placebo-controlled phase 3 trial limitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation. exposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis evidence_span: {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"} [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    Complete structured claim and evidence

  5. Burosumab binds and inhibits FGF23, the phosphate-wasting hormone targeted in the XLH trial.

    Burosumab anti-FGF23 antibody → Fibroblast growth factor 23 / FGF23 source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"}
    experimental_model
    Randomized double-blind placebo-controlled phase 3 trial
    exposure
    Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis
    limitations
    FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation.
    nutrient_topic
    Phosphorus research collection; topical membership is not evidence of a direct dietary effect. · Phosphorus
    organism
    Human
    plain_language
    The treatment targets the hormone driving phosphate loss, rather than only adding phosphate.
    primary_references
    [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    tissue_or_cell_type
    134 symptomatic adults with X-linked hypophosphatemia

    Phosphorus: metabolism, signaling and nutrient connections (2026-09-17) · lines 1180–1191

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled phase 3 trial · source_derived_draft · unverified_draft

    ### phosphorus-burosumab-target Burosumab binds and inhibits FGF23, the phosphate-wasting hormone targeted in the XLH trial. Condition category: normal nutrient_topic: Phosphorus research collection; topical membership is not evidence of a direct dietary effect. plain_language: The treatment targets the hormone driving phosphate loss, rather than only adding phosphate. organism: Human tissue_or_cell_type: 134 symptomatic adults with X-linked hypophosphatemia experimental_model: Randomized double-blind placebo-controlled phase 3 trial limitations: FGF23-mediated inherited disease, not simple nutritional deficiency. Pain and function outcomes require multiplicity-adjusted interpretation. exposure: Burosumab 1 mg/kg or placebo every four weeks; week-24 analysis evidence_span: {"source_cache": "artifacts/phosphorus-research/29947083.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e", "start_char": 0, "end_char": 2327, "text_sha256": "c1b305f00a7b9a569ccd197728d942ebbf55f9eaa164a95086d69a34608d3c4e"} [phosphorus-p29947083] A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018). https://pubmed.ncbi.nlm.nih.gov/29947083/ DOI: 10.1002/jbmr.3475
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards